

## Supplementary material:

### Taprogge et al: Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national MEDIRAD project

Supplementary Table 1: Ethics approval WP3

<i>Investigating centre</i>	<i>Ethical approval obtained</i>	<i>Ethics approval details</i>	<i>National, EudraCT or ClinicalTrials.gov Identifier</i>
<i>UKW</i>	9 <sup>th</sup> May 2019	Approved by the National Ethics Committee	EudraCT: 2019-002244-25
<i>UMR</i>	14 <sup>th</sup> May 2019	Approved by the National Ethics Committee	EudraCT: 2019-002244-25
<i>IUCT-O</i>	16 <sup>th</sup> Dec 2019	Approved by the National Ethics Committee	ID RCB : 2019-A01734-53
<i>RMH/ICR</i>	19 <sup>th</sup> March 2020	The study was approved by the East Midlands - Nottingham 1 Research Ethics Committee (20/EM/0022) and the institutional review board at the Royal Marsden Hospital	ClinicalTrials.gov: NCT04391244

Supplementary Table 2: Acquisition parameters used for <sup>131</sup>I imaging as part of the MEDIRAD WP3 study.

<i><sup>131</sup>I acquisition protocol</i>	
<i>Collimator</i>	High Energy
<i>Photopeak energy window</i>	364 keV ± 10% or ± 15%
<i>SPECT(/CT) Matrix</i>	128 x 128
<i>SPECT movement</i>	Body contour
<i>Projections</i>	2 x 30 (6° projection) or 2 x 36 (5° projection)
<i>Time per projection</i>	Adjusted based on measured count-rate for patient acquisition
<i>CT</i>	Standard low-dose protocol (if applicable)

**Supplementary Table 3: SPECT (/CT) reconstruction parameters used for  $^{131}\text{I}$  imaging as part of the MEDIRAD WP3 study.**

<i><math>^{131}\text{I}</math> reconstruction protocol</i>	
<i>Reconstruction</i>	OSEM (4 iterations, 10 subsets)
<i>Attenuation correction (AC)</i>	CTAC (One centre: Chang with $0.11\text{ cm}^{-1}$ @ 364 keV)
<i>Scatter correction</i>	Triple-Energy Window (TEW)
<i>Post-reconstruction filtering</i>	None